Search Results for keywords:"Veterinarians"

The Food and Drug Administration (FDA) is seeking public feedback, especially from veterinarians, about the use of cannabis-derived products in animals, with a focus on cannabidiol (CBD). They are interested in learning about trends in product usage, potential benefits, safety issues, and drug interactions among other concerns. This information will help enhance the understanding of these products' effects on animals. Comments can be submitted electronically or in written form until April 16, 2025, following specific instructions for including or excluding confidential information.

The Food and Drug Administration (FDA) is inviting public comments on their proposal to collect information regarding the compounding of animal drugs from bulk substances. This aligns with the requirements of the Paperwork Reduction Act of 1995, which mandates federal agencies to provide a 60-day notice for public feedback on information collection proposals. The FDA is particularly interested in comments about the necessity, accuracy, and efficiency of its information collection practices. The guidance, GFI #256, outlines situations where the FDA does not intend to enforce actions against pharmacists and veterinarians who compound these drugs, as long as no other appropriate treatments exist.